Non-muscle invasive bladder cancer remains amongst the most difficult malignancies to treat. The mainstay of treatment is BCG, yet this is often in short supply and difficult to obtain. These patients have a high rate of recurrence and are often left with limited treatment options due to significant comorbidities. This presentation discusses the treatment options for these patients and discusses how we can improve the outcomes in these notoriously difficult to treat patients.
Continuing Education Instructions and Disclosure Information:
Contact hours available until 10/11/22.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.
Faculty, Planners, and Speakers Conflict of Interest Disclosure:
Planning Committee Disclosures: There are no Planning Committee disclosures to declare.
Speakers Conflict of Interest Disclosure: Louis Spencer Krane, MD Speakers Bureau for Exact Sciences Other - Laser Technologies, Gulf South Lithotripsy
There are no other speaker disclosures to declare.
Commercial Support and Sponsorship: No commercial support or sponsorship declared.
Accreditation Statement: Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
The SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is also a provider approved by the California Board of Registered Nursing, Provider Number CEP 5556. Accreditation and approved provider status of CE in nursing does not imply ANCC-COA approval or endorsement of any product, advertising, or educational content. SUNA urges all participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.
Learning Outcome: After completing this education activity, the learner will be able to discuss the treatment options for patients with non-muscle invasive bladder cancer (NMIBC).